Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press188910.17650/1726-9776-2025-21-2-182-191REVIEWSОБЗОРЫReview of the effectiveness of nuclear magnetic resonance spectroscopy for prostate cancer diagnosisОбзор эффективности применения спектроскопии ядерного магнитного резонанса для диагностики рака предстательной железыhttps://orcid.org/0000-0001-7280-2553PerepukhovV. M.ПерепуховВ. М.
Russian Federation

Vladimir Maksimovich Perepukhov

Build. 1, 51 3rd Parkovaya St., Moscow 105425

Владимир Максимович Перепухов 

105425 Москва, 3-я Парковая ул., 51, стр. 1

alfarvp05@gmail.comhttps://orcid.org/0000-0002-4171-6211NyushkoK. M.НюшкоК. М.
Russian Federation

Build. 1, 51 3rd Parkovaya St., Moscow 105425; 11 Volokolamskoe Shosse, Moscow 125080

105425 Москва, 3-я Парковая ул., 51, стр. 1; 125080 Москва, Волоколамское шоссе, 11

https://orcid.org/0000-0002-3398-4128AlekseevB. Ya.АлексеевБ. Я.
Russian Federation

11 Volokolamskoe Shosse, Moscow 125080; 3 2nd Botkinskiy Proezd, Moscow 125284

125080 Москва, Волоколамское шоссе, 11; 125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0002-9787-8842MailyanO. A.МаилянО. А.
Russian Federation

3 2nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaНаучно-исследовательский институт урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииMedical Institute of Continuing Education, Russian Biotechnological UniversityМедицинский институт непрерывного образования ФГБОУ ВО «Российский биотехнологический университет»National Medical Research Radiological Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России060820252121821911301202528042025https://oncourology.abvpress.ru/oncur/article/view/1889

Prostate cancer (PCa) is the most common malignant neoplasm among men in Russia and one of the most common worldwide. PCa diagnosis, progression management, and evaluation of prognosis are performed using a combination of examinations: laboratory, instrumental, and various nomograms. The current methods of PCa diagnosis have limited sensitivity and specificity, therefore the search for new diagnostic methods is an important problem. Nuclear magnetic resonance (NMR) spectroscopy is a promising method allowing to detect malignant tumor-associated metabolites in biological liquids. According to some studies, PCa is associated with changes in levels of various metabolites in serum and plasma. This review presents the results of studies reporting on high effectiveness of NMR spectroscopy analysis of serum and plasma for PCa diagnosis.

Рак предстательной железы (РПЖ) – самое распространенное злокачественное новообразование в России среди мужчин и одно из самых распространенных в мире. Диагностика РПЖ, контроль течения и оценка прогноза развития заболевания выполняются с помощью комплекса обследований: лабораторных, инструментальных, а также различных номограмм. Существующие методы диагностики РПЖ ограничены по чувствительности и специфичности, поэтому поиск новых методов диагностики является актуальной задачей. Одним из перспективных диагностических подходов может стать спектроскопия ядерного магнитного резонанса (ЯМР), с помощью которой выполняется поиск ассоциированных со злокачественным новообразованием метаболитов в биологических жидкостях организма. По данным ряда исследований, РПЖ ассоциирован с изменениями концентраций различных метаболитов в сыворотке или плазме крови. В настоящем обзоре приведены результаты исследований, в которых сообщается о высокой эффективности использования ЯМР-спектроскопии для диагностики РПЖ с использованием для анализа сыворотки или плазмы крови

prostate cancermetabolomicsnuclear magnetic resonance spectroscopyNMR spectroscopyрак предстательной железыметаболомикаспектроскопия ядерного магнитного резонансаЯМР-спектроскопияState of oncological care in Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 262 p. (In Russ.).Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 262 с.Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI: 10.3322/caac.21834Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical guidelines on drug treatment of prostate cancer. RUSSCO practical guidelines, part 1. Zlokachestvennye opukholi = Malignant Tumors 2023;13(3s2): 640–60. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли 2023;13(3s2–1):640–60. DOI: 10.18027/2224-5057-2023-13-3s2-1-640-660Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268–78. DOI: 10.1038/nrc2351Kushlinskiy K.E., Storozhenko I.V., Sergeeva N.S. et al. Prostate cancer and prostate-specific antigen. Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2000;(1):44–8. (In Russ.).Кушлинский К.Е., Стороженко И.В., Сергеева Н.С. и др. Рак предстательной железы и простат-специфический антиген. Российский онкологический журнал 2000;(1):44–8.Sundaresan V.M., Smani S., Rajwa P. et al. Prostate-specific antigen screening for prostate cancer: diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol 2025;43(1):41–8. DOI: 10.1016/j.urolonc.2024.06.003Haythorn M.R., Ablin R.J. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark Med 2011;5(4):515–26. DOI: 10.2217/bmm.11.53Ploussard G., Nicolaiew N., Marchand C. et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol 2014;65(1):154–61. DOI: 10.1016/j.eururo.2012.05.049De la Taille A., Antiphon P., Salomon L. et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003;61(6):1181–6. DOI: 10.1016/s0090-4295(03)00108-0Ahmed H.U., El-Shater Bosaily A., Brown L.C. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389(10071):815–22. DOI: 10.1016/S0140-6736(16)32401-1Loeb S., Vellekoop A., Ahmed H.U. et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64(6):876–92. DOI: 10.1016/j.eururo.2013.05.049Van der Kwast T.H., Roobol M.J. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013;10(8):473–82. DOI: 10.1038/nrurol.2013.112Valerio M., Donaldson I., Emberton M. et al. Detection of clinically significant prostate cancer using magnetic resonance imaging – ultrasound fusion targeted biopsy: a systematic review. Eur Urol 2015;68(1):8–19. DOI: 10.1016/j.eururo.2014.10.026Mlynárik V. Introduction to nuclear magnetic resonance. Anal Biochem 2017;529:4–9. DOI: 10.1016/j.ab.2016.05.006Bleaney B. Jubilees of radio-frequency spectroscopy. Notes Rec R Soc Lond 1997;51(2):317–26.Günther H. NMR spectroscopy: basic principles, concepts and applications in chemistry. John Wiley & Sons, 2013.Cacciatore S., Loda M. Innovation in metabolomics to improve personalized healthcare. Ann N Y Acad Sci 2015;1346(1):57–62. DOI: 10.1111/nyas.12775Nicholson J.K., Lindon J.C., Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29(11):1181–9. DOI: 10.1080/004982599238047Jordan K.W., Nordenstam J., Lauwers G.Y. et al. Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum 2009;52(3):520–5. DOI: 10.1007/DCR.0b013e31819c9a2cTrock B.J. Application of metabolomics to prostate cancer. Urol Oncol 2011;29(5):572–81. DOI: 10.1016/j.urolonc.2011.08.002Ren J.L., Zhang A.H., Kong L., Wang X.J. Advances in mass spectrometry-based metabolomics for investigation of metabolites. RSC Adv 2018;8(40):22335–50. DOI: 10.1039/c8ra01574kNagana Gowda G.A., Gowda Y.N., Raftery D. Expanding the limits of human blood metabolite quantitation using NMR spectroscopy. Anal Chem 2015;87(1):706–15. DOI: 10.1021/ac503651eOverview of NMR spectroscopy-based metabolomics: opportunities and challenges. In: NMR-Based Metabolomics: Methods and Protocols. Eds.: G.A. Gowda, D. Raftery. Vol. 2037. New York, NY, USA: Humana Press, 2019. Pp. 3–14.Dumas M.E., Maibaum E.C., Teague C. et al. Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal Chem 2006;78(7):2199–208. DOI: 10.1021/ac0517085Sharma U., Jagannathan N.R. Metabolism of prostate cancer by Magnetic Resonance Spectroscopy (MRS). Biophys Rev 2020;12(5):1163–73. DOI: 10.1007/s12551-020-00758-6Lima A.R., Bastos Mde L., Carvalho M., Guedes de Pinho P. Biomarker discovery in human prostate cancer: an update in metabolomics studies. Transl Oncol 2016;9(4):357–70. DOI: 10.1016/j.tranon.2016.05.004Wishart D.S., Djoumbou Feunang Y., Marcu A. et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 2018;46(D1):D608–17. DOI: 10.1093/nar/gkx1089Nagana Gowda G.A., Raftery D. Biomarker discovery and translation in metabolomics. Curr Metabolomics 2013;1(3):227–40. DOI: 10.2174/2213235X113019990005Dakubo G.D., Parr R.L., Costello L.C. et al. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59(1):10–6. DOI: 10.1136/jcp.2005.027664Costello L.C., Feng P., Milon B. et al. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 2004;7(2):111–7. DOI: 10.1038/sj.pcan.4500712Costello L.C., Franklin R.B. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch Biochem Biophys 2016;611:100–12. DOI: 10.1016/j.abb.2016.04.014Eidelman E., Twum-Ampofo J., Ansari J., Minhaj Siddiqui M. The metabolic phenotype of prostate cancer. Front Oncol 2017;7:131. DOI: 10.3389/fonc.2017.00131Andersen M.K., Giskeødegård G.F., Tessem M.B. Metabolic alterations in tissues and biofluids of patients with prostate cancer. Curr Opin Endocrine Metabol Res 2020;10:23–8.Kwon H., Oh S., Jin X. et al. Cancer metabolomics in basic science perspective. Arch Pharm Res 2015;38(3):372–80. DOI: 10.1007/s12272-015-0552-4Warburg O. On the origin of cancer cells. Science 1956;123(3191):309–14. DOI: 10.1126/science.123.3191.309Sadeghi R.N., Karami-Tehrani F., Salami S. Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes. Tumour Biol 2015;36(4):2893–2905. DOI: 10.1007/s13277-014-2919-4Twum-Ampofo J., Fu D.X., Passaniti A. et al. Metabolic targets for potential prostate cancer therapeutics. Curr Opin Oncol 2016;28(3):241–7. DOI: 10.1097/CCO.0000000000000276Dueregger A., Schöpf B., Eder T. et al. Differential utilization of dietary fatty acids in benign and malignant cells of the prostate. PLoS One 2015;10(8):e0135704. DOI: 10.1371/journal.pone.0135704Zadra G., Loda M. Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities. Cold Spring Harb Perspect Med 2018;8(10):a030569. DOI: 10.1101/cshperspect.a030569Lloyd S.M., Arnold J., Sreekumar A. Metabolomic profiling of hormone-dependent cancers: a bird’s eye view. Trends Endocrinol Metab 2015;26(9):477–85. DOI: 10.1016/j.tem.2015.07.001Schipper R.G., Romijn J.C., Cuijpers V.M.J.I., Verhofstad A.A.J. Polyamines and prostatic cancer. Biochem Soc Trans 2003;31(2):375–80. DOI: 10.1042/bst0310375Feun L., You M., Wu C.J. et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008;14(11):1049–57. DOI: 10.2174/138161208784246199Qiu F., Huang J., Sui M. Targeting arginine metabolism pathway to treat arginine-dependent cancers. Cancer Lett 2015;364(1):1–7. DOI: 10.1016/j.canlet.2015.04.020Wang H., Zhang L., Fu Y. et al. CSL regulates AKT to mediate androgen independence in prostate cancer progression. Prostate 2016;76(2):140–50. DOI: 10.1002/pros.23104Mithal P., Allott E., Gerber L. et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol 2014;21(12):1209–14. DOI: 10.1111/iju.12571Tennakoon J.B., Shi Y., Han J.J. et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene 2014;33(45):5251–61. DOI: 10.1038/onc.2013.463Zadra G., Photopoulos C., Tyekucheva S. et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014;6(4):519–38. DOI: 10.1002/emmm.201302734Sanli T., Steinberg G.R., Singh G., Tsakiridis T. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther 2014;15(2):156–69. DOI: 10.4161/cbt.26726Kumar D., Gupta A., Mandhani A., Narain Sankhwar S. NMR spectroscopy of filtered serum of prostate cancer: a new frontier in metabolomics. Prostate 2016;76(12):1106–19. DOI: 10.1002/pros.23198Zniber M., Vahdatiyekta P., Huynh T.P. Discrimination of serum samples of prostate cancer and benign prostatic hyperplasia with 1 H-NMR metabolomics. Anal Methods 2024;16(41):7043–53. DOI: 10.1039/d4ay01109kKumar D., Gupta A., Mandhani A., Narain Sankhwar S. Metabolomics-derived prostate cancer biomarkers: fact or fiction? J Proteome Res 2015;14(3):1455–64. DOI: 10.1021/pr5011108Gomez-Cebrian N., García-Flores M., Rubio-Briones J. et al. Targeted metabolomics analyses reveal specific metabolic alterations in high-grade prostate cancer patients. J Proteome Res 2020;19(10):4082–92. DOI: 10.1021/acs.jproteome.0c00493Zhang X., Xia B., Zheng H. et al. Identification of characteristic metabolic panels for different stages of prostate cancer by 1H NMR-based metabolomics analysis. J Translat Med 2022;20(1):275. DOI: 10.1186/s12967-022-03478-5